Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
AstraZeneca plc, a British-Swedish pharmaceutical and biotechnology company, is reportedly withdrawing its COVID-19 vaccine worldwide. The company made the decision months after admitting in court there is a rare side effect.
But then again, according to Channel News Asia, AstraZeneca did not say this was the reason for the pullout of the vaccines. Rather, the company said it was due to “commercial reasons.”
Taking Back the COVID-19 Vaccines Years After Release
AstraZeneca said on Tuesday, May 7, the withdrawal of its vaccines around the world is already underway. It stressed that this is due to a "surplus of available updated vaccines" since the pandemic.
Moreover, the pharmaceutical and biotech firm announced it would also retract the vaccine Vaxzevria's marketing authorizations in Europe. AstraZeneca added that it is no longer producing its COVID-19 vaccine, so supply to the market has also stopped.
“As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company’s spokesman said in a statement. “This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.”
Reported Side Effects of Vaxzevria
AstraZeneca reportedly admitted in court documents that the vaccine has side effects like low platelet counts and blood clots. British newspapers stated that based on legal documents, the company's vaccine may cause TTS, but in very rare cases. World Health Organization (WHO), said this condition called Thrombosis with Thrombocytopenia Syndrome is a serious and life-threatening negative effect.
“It is admitted that the AZ vaccine can, in very rare cases, cause TTS,” AstraZeneca said in court documents in February. “The causal mechanism is not known.”
UK’s The Independent reported that AstraZeneca’s admission came after it was sued in the U.K. The class action lawsuits alleged that the company’s vaccine caused deaths and severe injuries, and claimants are seeking damages up to £100 million for around 50 supposed victims.
Photo by: Mufid Majnun/Unsplash
